BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18308671)

  • 1. Visual vignette. Prolactinoma.
    Mayrin JV; Donahue JE; Laufgraben MJ
    Endocr Pract; 2008 Mar; 14(2):256. PubMed ID: 18308671
    [No Abstract]   [Full Text] [Related]  

  • 2. Medical Management of a Prolactinoma in a 15-Year-Old Girl.
    Bowling MS; Zamudio A; Jaffery F
    J Pediatr; 2018 Sep; 200():287-287.e1. PubMed ID: 29685620
    [No Abstract]   [Full Text] [Related]  

  • 3. [Selection of management tactics in treatment of giant prolactin-secreting pituitary adenomas].
    Astaf'eva LI; Kadashev BA; Kalinin PL; Kutin MA; Faĭzullaev RB; Sidneva IuG; Tenedieva VD; Tropinskaia OF
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (2):23-8; discussion 28-9. PubMed ID: 19569545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactin, prolactin disorders, and dopamine agonists during pregnancy.
    Levin G; Rottenstreich A
    Hormones (Athens); 2019 Jun; 18(2):137-139. PubMed ID: 30341577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
    Neff LM; Weil M; Cole A; Hedges TR; Shucart W; Lawrence D; Zhu JJ; Tischler AS; Lechan RM
    Pituitary; 2007; 10(1):81-6. PubMed ID: 17285366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Giant prolactinomas presenting as skull base tumors.
    Minniti G; Jaffrain-Rea ML; Santoro A; Esposito V; Ferrante L; Delfini R; Cantore G
    Surg Neurol; 2002 Feb; 57(2):99-103; discussion 103-4. PubMed ID: 11904200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When to discontinue treatment of prolactinoma?
    Wass JA
    Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
    [No Abstract]   [Full Text] [Related]  

  • 8. [Some issues in the diagnosis and treatment of hyperprolactinemia].
    Jin ZM
    Zhonghua Fu Chan Ke Za Zhi; 2008 Apr; 43(4):241-3. PubMed ID: 18843959
    [No Abstract]   [Full Text] [Related]  

  • 9. Visual vignette. Macroprolactinoma.
    Orrego JJ
    Endocr Pract; 2008 Apr; 14(3):393. PubMed ID: 18463052
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 11. [Recurrence of prolactinoma surveyed. Hormone therapy can safely be withdrawn for a long time in patients with normalized prolactin levels and invisible tumor].
    Werner S
    Lakartidningen; 2004 Oct; 101(41):3162-3. PubMed ID: 15517713
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
    Bronstein MD
    Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
    [No Abstract]   [Full Text] [Related]  

  • 14. Double pituitary prolactinoma.
    de Oliveira Andrade LJ; Santos França L; Santos França L; Cordeiro de Almeida MA
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4848-9. PubMed ID: 21051581
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical practice. Prolactinomas.
    Klibanski A
    N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical practice. Prolactinoma.
    Schlechte JA
    N Engl J Med; 2003 Nov; 349(21):2035-41. PubMed ID: 14627789
    [No Abstract]   [Full Text] [Related]  

  • 17. Sjögren's Syndrome Accompanied by Prolactinoma: a case report and literature review.
    Oh YJ; Lee WS; Yoo WH; Hahm JR; Kim HO; Suh YS; Lee SI; Cheon YH
    Int J Rheum Dis; 2017 Nov; 20(11):1823-1826. PubMed ID: 26355497
    [No Abstract]   [Full Text] [Related]  

  • 18. Macroprolactinemia in patients with prolactinomas: prevalence and clinical significance.
    Elenkova A; Genov N; Abadzhieva Z; Kirilov G; Vasilev V; Kalinov K; Zacharieva S
    Exp Clin Endocrinol Diabetes; 2013 Apr; 121(4):201-5. PubMed ID: 23595795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Macroprolactinoma].
    von Werder K
    Dtsch Med Wochenschr; 1996 Jul; 121(30):962. PubMed ID: 8777896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.